X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Start of A Multi-Drug Trial For Precision Medicine Cancer

Content Team by Content Team
28th November 2022
in Clinical Trials, News

A multi-drug, precision medicine trial involving Roche, the University of Manchester, and Cancer Research UK has begun for patients with rare cancers who need additional treatment options. The DETERMINE study is one of the only platform trials using precision medicine in the world that is enrolling both adult and paediatric patients with any uncommon cancer kind.

The purpose of the study is to determine whether existing treatments, particularly those that are approved for use in patients with cancer of less common occurrences, might also be beneficial in such cases. Patients who meet the criteria will have undergone genetic testing and learned that they have one of the precise gene mutations in their cancer that the particular medicine under consideration can target.

Due to the trial’s nature, the Cancer Drug Fund (CDF) will be consulted for any medication that appears to be effective for patients. The CDF will then decide whether to gather additional information and decide if the medication might be used as a standard treatment option throughout the NHS.

The experiment is being overseen by the University of Manchester’s Center for Drug Development, which is part of Cancer Research UK. Roche, meanwhile, is supplying seven of its targeted medications for the first assessment. As the trial advances, other pharmaceutical companies are encouraged to participate and supply medications.

The Christie NHS Foundation Trust is the first trial site, and the Royal Marsden NHS Foundation Trust, the University of Glasgow, and the University of Birmingham will be the next.

This platform study is a key milestone in Cancer Research UK’s commitment to developing new treatments for cancer patients who sorely need them, said executive director of research and innovation, Iain Foulkes, at the organization. This experiment offers a simple route to providing long-term patient access to potentially life-saving therapies that weren’t previously available to patients with uncommon diseases, he continued, by looking at already-approved medications and collaborating with the Cancer Drugs Fund.

It is crucial that they enhance their research efforts for patients with uncommon cancer because there are frequently few treatment options available, according to the chief investigator for the DETERMINE trial at the University of Manchester, Dr. Matthew Krebs. Genetic testing has advanced, and they now know that some uncommon tumours possess genetic mutations that could benefit from targeted therapies that are now only available for more widespread cancer types.

Every year, 22 out of every 100 new cases of cancer in the world are uncommon malignancies. However, despite their prevalence, people with uncommon cancers have fewer therapy options.

Previous Post

A Single, Linked Foundation Is Transforming Digital Trials

Next Post

AI Customizes Synthesized DNA For Medication Development

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

AI Customizes Synthesized DNA For Medication Development

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In